Auron_TM-GRADIENT-logo_CMYK_.png
Auron Presents New Preclinical Data for AUTX-703 in AML at ASH Annual Meeting
December 09, 2024 07:00 ET | Auron Therapeutics Inc.
Data demonstrate dose dependent survival advantage with AUTX-703 in primary patient-derived orthotopic AML model IND submissions on track for late 2024 NEWTON, Mass., Dec. 09, 2024 (GLOBE...
Auron_TM-GRADIENT-logo_CMYK_.png
Auron to Present New Preclinical Data for AUTX-703 at 2024 ASH Meeting
November 05, 2024 09:00 ET | Auron Therapeutics Inc.
NEWTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...
Auron_TM-GRADIENT-logo_CMYK_.png
Auron Presents New Preclinical Data for Lead Program AUTX-703 Across Multiple Cancer Types
October 24, 2024 07:00 ET | Auron Therapeutics Inc.
Treatment with AUTX-703 resulted in notable cell differentiation and tumor growth inhibition in various primary cancer models AUTX-703 IND submission on track for late 2024 NEWTON, Mass. , Oct. 24,...
Auron_TM-GRADIENT-logo_CMYK_.png
Auron Announces Poster Presentation at 2024 PCF Annual Scientific Retreat
October 11, 2024 08:00 ET | Auron Therapeutics Inc.
NEWTON, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...
Auron_TM-GRADIENT-logo_CMYK_.png
Auron to Present AUTX-703 Preclinical Data 2024 ENA Symposium
October 09, 2024 08:00 ET | Auron Therapeutics Inc.
NEWTON, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...
Auron_TM-GRADIENT-logo_CMYK_.png
Auron Presents Preclinical Data at American Chemical Society Annual Meeting
August 19, 2024 08:00 ET | Auron Therapeutics Inc.
NEWTON, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...
Auron_TM-GRADIENT-logo_CMYK_.png
Auron Announces Oral Presentation on Preclinical Data from Proprietary AURIGIN™ Platform at the AI in Biomedicine Keystone Symposia
May 01, 2024 08:00 ET | Auron Therapeutics Inc.
NEWTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...
Auron_TM-GRADIENT-logo_CMYK_.png
Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual Meeting
April 09, 2024 16:30 ET | Auron Therapeutics Inc.
Preclinical data from lead program addressing AURIGIN-identified KAT2A/B target showed significant cell state shift and tumor growth inhibition across multiple primary cancer models AURIGIN overview...
Auron_TM-GRADIENT-logo_CMYK_.png
Auron Announces Poster Presentations at 2024 AACR Annual Meeting
March 06, 2024 08:00 ET | Auron Therapeutics Inc.
NEWTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic...
Auron_TM-GRADIENT-logo_CMYK_.png
Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform
February 08, 2024 08:00 ET | Auron Therapeutics Inc.
AUTX-703 has demonstrated potent growth inhibition in preclinical models of solid tumors and a hematological malignancy An overview of the Company’s AURIGIN platform to be presented at the American...